![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
Armo scooped up by Lilly for $1.5bn
Executive Summary
Eli Lilly & Co. will pay $50 per share (a 79% premium) or approximately $1.5bn to acquire immuno-oncology firm Armo BioSciences Inc. The deal provides a swift exit for Armo shareholders, as the company just went public through a $17 per share/$137mm initial public offering in January of this year.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice